MX2010002938A - Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. - Google Patents

Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.

Info

Publication number
MX2010002938A
MX2010002938A MX2010002938A MX2010002938A MX2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A MX 2010002938 A MX2010002938 A MX 2010002938A
Authority
MX
Mexico
Prior art keywords
treating
beta
butan
thiazol
pyrrolidine
Prior art date
Application number
MX2010002938A
Other languages
English (en)
Spanish (es)
Inventor
Arun K Ghosh
Geoffrey M Bilcer
Chunfeng Liu
Thippeswamy Devasamudram
Hui Lei
Lisa M Swanson
Sudha V Ankala
John C Lilly
Original Assignee
Comentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comentis Inc filed Critical Comentis Inc
Publication of MX2010002938A publication Critical patent/MX2010002938A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2010002938A 2007-09-24 2008-09-24 Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. MX2010002938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97479307P 2007-09-24 2007-09-24
PCT/US2008/077537 WO2009042694A1 (en) 2007-09-24 2008-09-24 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating

Publications (1)

Publication Number Publication Date
MX2010002938A true MX2010002938A (es) 2010-04-01

Family

ID=40343545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002938A MX2010002938A (es) 2007-09-24 2008-09-24 Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.

Country Status (8)

Country Link
US (1) US8299267B2 (enExample)
EP (1) EP2205596A1 (enExample)
JP (1) JP5055432B2 (enExample)
KR (1) KR20100059919A (enExample)
CN (1) CN101868457B (enExample)
CA (1) CA2699787A1 (enExample)
MX (1) MX2010002938A (enExample)
WO (1) WO2009042694A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101868457B (zh) 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
MX2012002730A (es) * 2009-09-04 2012-07-20 Tactical Therapeutics Inc Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
EP2486006A4 (en) * 2009-10-05 2013-05-01 Comentis Inc SULFONAMIDO PYRROLIDINE COMPOUNDS THAT INHIBIT BETA SECRETASE ACTIVITY AND METHODS OF USE THEREOF
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US20120053200A1 (en) * 2010-09-01 2012-03-01 Harald Mauser Bace 2 inhibitors
KR20150021036A (ko) 2012-06-14 2015-02-27 다이이찌 산쿄 가부시키가이샤 피페리디닐피라졸로피리딘 유도체
CN105669365B (zh) * 2016-03-04 2022-06-21 中国科学院上海有机化学研究所 含二氟烷基取代的芳基或杂芳基化合物、制备方法和应用
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN110117237B (zh) * 2018-02-05 2024-02-02 中国科学院上海有机化学研究所 一种芳香腈或烯基腈类化合物的制备方法
CN110642789B (zh) * 2019-11-25 2020-05-26 天津凯莱英制药有限公司 2-氯嘧啶-4-甲酸类化合物的连续性合成方法
CN112321515A (zh) * 2020-10-21 2021-02-05 上海馨远医药科技有限公司 一种手性1-叔丁基-3-甲基-6-甲基哌嗪-1,3-二甲酸酯的制备方法
US20250115636A1 (en) * 2022-02-03 2025-04-10 Purdue Research Foundation Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use
US12191004B2 (en) 2022-06-27 2025-01-07 Microsoft Technology Licensing, Llc Machine learning system with two encoder towers for semantic matching

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
TW282460B (enExample) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
WO2001044199A1 (en) 1999-12-16 2001-06-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2004528266A (ja) 2000-04-12 2004-09-16 インプリクス リミテッド 薬物送達用組成物
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
AU2002239727C1 (en) 2000-12-28 2005-12-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
US20060234944A1 (en) 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
EP1448218A4 (en) 2001-10-23 2009-01-14 Oklahoma Med Res Found BETA SECRETASE INHIBITORS AND METHODS OF USE
GEP20074171B (en) 2001-11-08 2007-07-25 Elan Pharm Inc N,n'−substituted−1,3−diamino−2−hydroxypropane derivatives
EP1453788A1 (en) 2001-12-06 2004-09-08 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
EP1503980A2 (en) 2002-02-27 2005-02-09 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
US7807618B2 (en) 2002-05-20 2010-10-05 The Board Of Regents Of The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
MXPA05002508A (es) 2002-09-06 2005-06-03 Elan Pharm Inc Derivados de profarmaco 1,3-diamino-2-hidroxipropano.
EP1562897B1 (en) 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
AU2004265298A1 (en) 2003-08-08 2005-02-24 Pharmacopeia, Inc. Cyclic amine BACE-1 inhibitors having a benzamide substituent
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Bace 저해효능을 가진 신규한 술폰 아미드 유도체
EP1697308B1 (en) 2003-12-19 2014-03-19 Merck Sharp & Dohme Corp. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
JP2008502684A (ja) 2004-06-15 2008-01-31 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−3−イル化合物
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006034296A2 (en) 2004-09-17 2006-03-30 Comentis, Inc. Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
EP1797052A1 (en) * 2004-09-17 2007-06-20 Comentis, Inc. Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
CN100475786C (zh) * 2005-02-18 2009-04-08 中国科学院上海药物研究所 一类4-羟基戊酰胺类化合物及其制备方法和用途
US7745470B2 (en) 2005-03-10 2010-06-29 Bristol-Myers Squibb Company Isophthalates as beta-secretase inhibitors
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR054363A1 (es) 2005-05-23 2007-06-20 Astrazeneca Ab Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6
AR054044A1 (es) 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US7476764B2 (en) 2005-08-04 2009-01-13 Bristol-Myers Squibb Company Phenylcarboxyamides as beta-secretase inhibitors
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
CA2664130A1 (en) 2006-09-21 2008-03-27 Merck & Co., Inc. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
CN101821238A (zh) 2007-07-26 2010-09-01 科门蒂斯公司 抑制β-分泌酶(BETA-SECRETASE)活性的间苯二酰胺衍生物
CN101868457B (zh) 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
WO2010002994A1 (en) 2008-07-01 2010-01-07 Purdue Research Foundation Nonpeptide hiv-1 protease inhibitors
CA2739875A1 (en) 2008-10-10 2010-04-15 Comentis, Inc. Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
JP2012505241A (ja) 2008-10-10 2012-03-01 パーデュー・リサーチ・ファウンデーション アルツハイマー病の治療用組成物
JP2012509352A (ja) 2008-11-20 2012-04-19 パーデュー・リサーチ・ファウンデーション Bace1のキナゾリン阻害剤および使用方法
US8859590B2 (en) 2008-12-05 2014-10-14 Purdue Research Foundation Inhibitors of BACE1 and methods for treating Alzheimer's disease
US20120214802A1 (en) 2009-03-25 2012-08-23 Bilcer Geoffrey M Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
EP2486006A4 (en) 2009-10-05 2013-05-01 Comentis Inc SULFONAMIDO PYRROLIDINE COMPOUNDS THAT INHIBIT BETA SECRETASE ACTIVITY AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
JP2010540462A (ja) 2010-12-24
CA2699787A1 (en) 2009-04-02
CN101868457B (zh) 2013-02-13
CN101868457A (zh) 2010-10-20
US20100286170A1 (en) 2010-11-11
US8299267B2 (en) 2012-10-30
WO2009042694A1 (en) 2009-04-02
EP2205596A1 (en) 2010-07-14
JP5055432B2 (ja) 2012-10-24
KR20100059919A (ko) 2010-06-04

Similar Documents

Publication Publication Date Title
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
NO20083207L (no) Inhibitorer av IAP
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201170344A1 (ru) Азаиндольные ингибиторы iap
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
MX2010007543A (es) Inhibidores de iap.
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
TW200745066A (en) Novel PTP1B inhibitors
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
FG Grant or registration